Last updated: February 20, 2026
What is the current status of clinical trials for etretinate?
Etretinate is a derivative of acitretin, historically used for severe psoriasis treatment. Its use has declined due to safety concerns, especially its long half-life and teratogenicity. The drug is largely phased out from clinical development. There are no recent or ongoing registered clinical trials for etretinate in major databases like ClinicalTrials.gov or EU Clinical Trials Register. The last recorded trials date back to the 1980s and 1990s, primarily focusing on psoriasis and keratinization disorders.
Why has clinical development of etretinate stalled?
- Safety concerns: High teratogenic risk and chronic toxicity limit its therapeutic window.
- Pharmacokinetics: Long half-life (up to 120 days) complicates dosing and monitoring.
- Regulatory stance: Withdrawal or reclassification by agencies due to safety issues.
- Market shift: Replacement by safer retinoids such as acitretin, etanercept, and biologics.
What is the current market landscape for retinoids and related drugs?
The dermatology therapeutics market, including psoriasis treatments, is characterized by:
- A global value of approximately USD 20 billion in 2022, expected to grow at 7% annually (Novartis, 2022).
- Key players such as AbbVie, Amgen, Johnson & Johnson, and Novartis dominate biologics and systemic agents.
- Emollients and topical therapies constitute a significant segment but are complemented by systemic retinoids.
How does etretinate compare with current therapies?
| Aspect |
Etretinate |
Acitretin |
Apremilast |
Biologics (e.g., Adalimumab) |
| Safety profile |
High teratogenicity |
Better, but teratogenic |
Well-tolerated, oral |
Effective but costly, injectable |
| Pharmacokinetics |
Long half-life (~120 days) |
Shorter (~49 hours) |
Short half-life (~5 hours) |
Variable, depends on the agent |
| Current use |
No, phased out |
Approved, limited safety |
Approved for psoriasis |
Approved for moderate to severe psoriasis |
What is the market outlook for retinoids and related therapies?
The anti-psoriatic drugs market is projected to reach USD 25 billion by 2027, with biologics accounting for 65%. Retinoids like acitretin retain niche roles in resistant cases or in patients where biologics are contraindicated. The demand for topical agents remains steady, but systemic agents face pressure due to safety concerns.
Future prospects for etretinate
- No significant development or trial activity suggests it will not reenter the clinical space.
- Its long pharmacokinetic profile poses challenges in safety and patient compliance.
- Replacement by modern agents reduces the likelihood of rekindling interest.
What potential niche or alternative markets exist for etretinate?
The drug could theoretically have a role in developing niche formulations or topical applications, but:
- Its toxicity profile minimizes practical use.
- Existing agents outperform etretinate in safety and efficacy.
Market projection summary
| Year |
Market Size (USD billion) |
CAGR |
Comments |
| 2023 |
20 |
— |
Mature market with dominant biologics and generics |
| 2027 |
25 |
7% |
Growth driven by biologic adoption and expanding psoriasis market |
Key barriers to market re-entry
- Safety concerns remain unresolved.
- Existing alternative drugs outperform etretinate.
- Regulatory and clinical development costs unlikely to justify re-establishment.
Key Takeaways
- No recent clinical trials or active development projects for etretinate.
- The drug has been replaced by safer, more effective agents.
- The psoriasis and dermatology markets continue to grow, driven by biologics, but etretinate's profile prevents market re-entry.
- Industry focus shifts to novel biologics, small molecules, and topical innovations.
- Existing market segments are mature; new development for etretinate is unlikely.
FAQs
1. Why is etretinate no longer used?
It has a high risk of teratogenicity, long half-life, and chronic toxicity, outweighing any potential benefits.
2. Are there any ongoing efforts to regenerate etretinate?
No active clinical or development efforts are known; focus has shifted entirely to newer drugs.
3. How do retinoids like acitretin compare with etretinate?
Acitretin has a shorter half-life, better safety profile, and is approved for clinical use; etretinate is phased out.
4. Can etretinate be repurposed for any other medical applications?
Its toxicity profile limits repurposing options; no current evidence suggests viable alternative uses.
5. What are the main competitors to etretinate in psoriasis treatment?
Biologics (e.g., adalimumab, secukinumab) and newer oral agents like apremilast dominate.
References
[1] Novartis. (2022). Skin Disease Pipeline and Market Report.
[2] ClinicalTrials.gov. (2023). Search results for "etretinate."
[3] European Medicines Agency. (2019). Summary of Product Characteristics for acitretin.
